Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCVax-L and T-cell Transfer in Recurrent Ovarian Cancer
NCT00603460Phase 2Withdrawn
- Sponsor
- University of Pennsylvania
- Start
- Jan 2012
- Primary completion
- Jan 2013
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of DCVax-L in ovarian cancer and primary peritoneal cancer (PPC) (3 arms), sponsored by University of Pennsylvania. Primary endpoints: Progression-Free Survival at 6 months, Feasibility and Safety of T-cell Transfer and DCVax-L and 2 more. Planned start Jan 2012; status: withdrawn.
02
Drugs
DCVax-L
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00603460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00603460.